Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors

✍ Scribed by Michael D. Moore; Michael J. McGarvey; Rebecca A. Russell; Bryan R. Cullen; Myra O. McClure

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 241 KB
• Volume: 7
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.739

✦ Synopsis

Abstract

Background

There has been much research into the use of RNA interference (RNAi) for the treatment of human diseases. Many viruses, including hepatitis B virus (HBV), are susceptible to inhibition by this mechanism. However, for RNAi to be effective therapeutically, a suitable delivery system is required.

Methods

Here we identify an RNAi sequence active against the HBV surface antigen (HBsAg), and demonstrate its expression from a polymerase III expression cassette. The expression cassette was inserted into two different vector systems, based on either prototype foamy virus (PFV) or adeno‐associated virus (AAV), both of which are non‐pathogenic and capable of integration into cellular DNA. The vectors containing the HBV‐targeted RNAi molecule were introduced into 293T.HBs cells, a cell line stably expressing HBsAg. The vectors were also assessed in HepG2.2.15 cells, which secrete infectious HBV virions.

Results

Seven days post‐transduction, a knockdown of HBsAg by approximately 90%, compared with controls, was detected in 293T.HBs cells transduced by shRNA encoding PFV and AAV vectors. This reduction has been observed up to 5 months post‐transduction in single cell clones. Both vectors successfully inhibited HBsAg expression from HepG2.2.15 cells even in the presence of HBV replication. RT‐PCR of RNA extracted from these cells showed a reduction in the level of HBV pre‐genomic RNA, an essential replication intermediate and messenger RNA for HBV core and polymerase proteins, as well as the HBsAg messenger RNA.

Conclusions

This work is the first to demonstrate that delivery of RNAi by viral vectors has therapeutic potential for chronic HBV infection and establishes the ground work for the use of such vectors in vivo. Copyright © 2005 John Wiley & Sons, Ltd.